Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: Investors struggle with United front for FREEDOM

This article was originally published in Scrip

Executive Summary

In a month where investors have seen wide gyrations in share prices as the markets expect the first, but maybe not the last, European sovereign debt default, one biotechnology company, United Therapeutics,seems to have generated its own additional volatility but for all the wrong reasons. On 24 August, United reported the results of its Freedom-C2 Phase III clinical study for the drug oral treprostinil for pulmonary hypertension (PAH) (scripintelligence.com , 25 August 2011,). The study failed to meet the primary endpoint in the six-minute walk test (6-MW) compared to placebo and the share price of United finished the week down just under 20% against the Nasdaq Biotech Index (of which, United is a significant component) which finished the week with a slight gain.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC014243

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel